乳腺癌与甲状腺疾病的关系及乳腺钠碘转运体功能调控的研究
|
摘要
研究背景与目的
乳腺癌是严害威胁妇女心身健康的恶性肿瘤,在女性恶性肿瘤中其发病率和死亡率均居前列。在我国一些大城市中乳腺癌的发病率逐年递增,已跃居女性恶性肿瘤的首位。乳腺与甲状腺同属于垂体激素的靶器官,内分泌功能的变化与腺体疾病的发生发展有着密切的关系,乳腺组织的细胞癌变后仍具有激素受体功能,其原来所依赖的激素仍然调节着肿瘤细胞的生长。甲状腺激素在正常乳腺的发育和分化过程中起着促进作用。甲状腺激素可直接调控机体的生长和细胞的增殖,其含量的不足或过量均可改变垂体前叶和靶器官激素及化学致癌因子的代谢,因此认为乳腺癌的病程演进可能会受到甲状腺激素含量高低不同的影响。甲状腺激素对乳腺癌的作用仍不明,有可能既是肿瘤细胞形成的促进因子,也是对抗肿瘤细胞形成和生长的保护因子。研究发现促甲状腺激素受体和甲状腺激素受体在乳腺组织中有表达,反过来雌激素也影响着甲状腺的发育、生理及病理过程。本研究探讨甲状腺疾病与乳腺癌之间的相关性,了解甲状腺疾病对乳腺癌患者预后的影响。
根据国家中医药管理局颁布的《中医病症疗效标准》ZY/T001.2-94将乳腺癌分为3型：肝郁痰凝证、冲任失调证、正虚毒炽证。而甲状腺疾病则属于中医“瘿病”范畴,瘿病的发生主要与情志内伤、饮食及水土失宜有关。在致病因素作用下,肝郁不舒,脾失健运,脏腑失调,经络阻滞,导致气滞、血瘀、痰凝结于颈部而发病。此外,其发病与肝肾不足、六淫外感也有一定关系。常见证候有肝气郁结、肝郁脾虚、肝肾阴虚、肝阳上亢等。甲状腺疾病和乳腺癌的发生均与肝、脾、肾三脏有密切关系,可见两者的病因病机在中医理论的角度也存在相关性。本研究通过调查伴随甲状腺疾病的乳腺癌患者和甲状腺正常的乳腺癌患者的临床症状及症状分级量化值,探讨伴随甲状腺疾病的乳腺癌患者的证型分布情况,了解甲状腺疾病是否影响乳腺癌患者的中医证型分布。
钠碘转运体(Na+/I-Symporter, NIS)是一种糖化膜蛋白,即“碘泵”,其功能主要是借助于钠/钾交换而产生的细胞内外钠离子浓度梯度来转运血液内活性碘进入细胞,使胞内碘含量浓聚为血浆的20-100倍。NIS浓聚碘是甲状腺激素生物合成、诊断甲状腺核素显像以及甲亢、甲状腺肿瘤放射性碘治疗的基础。已经证实哺乳期的乳腺导管细胞上表达NIS并能浓聚碘,研究发现约85%的ER阳性乳腺癌及其转移组织细胞表面存在大量NIS,可主动将血液中的碘转运到乳腺癌组织,使其碘浓聚远高于正常组织,并发现87%的浸润性乳腺癌和83%的导管内癌表达NIS,而正常乳腺组织无NIS表达,但乳腺癌组织摄碘能力并没因为NIS表达的增加而增加。用放射性碘治疗恶性肿瘤的是肿瘤综合治疗的方法之一,而放射性碘发挥杀伤肿瘤细胞效应的基础是肿瘤细胞必须具有摄碘能力,但乳腺癌组织摄取碘的能力较低,使放射性碘治疗难以发挥效应。研究发现催乳激素、雌激素、cAMP刺激物、维甲酸类,糖皮质激素通过增加NIS基因表达以增强乳腺癌细胞的碘摄取。
昆布(Thallus japonica)是大叶藻科植物大叶藻的全草,俗称“海带”,具有软坚散结、利水泄热等功效,昆布是一种含碘量很高的海藻,碘对维持甲状腺与乳腺组织细胞的正常功能具有重要作用。昆布中含有很多活性成分,它的大部分活性成分与它的多糖成分关系密切,目前对昆布多糖的研究越来越受到重视。昆布多糖是一种β-1,3葡聚糖的聚合物,可以通过激活巨噬细胞,产生细胞毒性作用,抑制肿瘤细胞增殖而杀伤肿瘤细胞；也可以通过抑制肿瘤血管生成而抑制肿瘤生长。本课题主要研究昆布多糖对乳腺癌细胞(MCF-7) NIS基因和蛋白表达的影响,并探讨其与细胞摄碘功能之间的关系。
第一部分乳腺癌与甲状腺疾病关系的临床研究
目的
调查乳腺癌患者中甲状腺疾病的发病率,通过与对照组中甲状腺疾病的发病率比较,初探乳腺癌与甲状腺疾病之间的关系；初步了解甲状腺疾病对乳腺癌患者预后的影响。
方法
采用临床非随机对照研究的方法,选取我院可手术乳腺癌患者100例作为乳腺癌组,选取体检中心体检者100例作为对照组,分别接受甲状腺彩超、甲状腺抗体2项(TPOAb、TgAb)及甲功5项(TT3、TT4、FT3、FT4、TSH)检查,分别统计两组患者的TT3、TT4、FT3、FT4、TSH值,TPOAb及TgAb阳性率,甲状腺左右叶体积,甲状腺疾病的发病率。分别统计伴随甲状腺疾病的乳腺癌患者及甲状腺正常的乳腺癌患者的病理及生物学特征。分别统计两组患者的年龄、月经状况、体重指数(BMI)等基线特征。
结果
乳腺癌组和对照组的甲状腺左右叶体积大小比较,差异无统计学意义(P>0.05)；两组患者甲状腺疾病的总发病率分别为62%和38%,差异有统计学意义(P<0.05)；两组患者之间的TT3、TT4、FT3、FT4、TSH值比较,差异均无统计学意义(P>0.05)；两组患者之间的甲状腺单发结节、甲状腺腺瘤、甲状腺囊腺瘤、甲状腺囊肿、桥本氏甲状腺炎、甲亢、甲减、亚临床甲亢、亚临床甲减的发病率比较,差异均无统计学意义(P>0.05)；与对照组相比较,乳腺癌组的甲状腺多发结节、结节性甲状腺肿的发病率高,差异有统计学意义(P<0.05)；与对照组比较,乳腺癌组的TPOAb和TgAb性的发病率高,差异有统计学意义(P<0.05)；与甲状腺正常的乳腺癌患者相比较,伴随甲状腺疾病的乳腺癌患者的Her-2阳性的表达率高,Ki-67>30%的增殖率增高,差异均有统计学意义(P<0.05)；两组的区域淋巴结、组织学分级、病理分期、脉管癌栓、雌激素受体、孕激素受体等病理特征比较,差异均无统计学意义(P>0.05)。两组患者的年龄、月经状况、BMI等基线特征比较,差异均无统计学意义(P>0.05)；
结论
乳腺癌组的甲状腺疾病总发病率高于对照组；乳腺癌患者的甲状腺多发结节、结节性甲状腺肿的发病率较高,提示乳腺癌患者多伴发甲状腺病理形态方面的改变；乳腺癌组TPOAb及TgAb阝日性率高,提示乳腺癌与自身免疫性甲状腺疾病可能相关；伴随甲状腺疾病的乳腺癌患者Her-2阳性的表达率较高,Ki-67增殖率较高,提示可能预后较差；而两组的区域淋巴结、组织学分级、病理分期、脉管癌栓、雌激素受体、孕激素受体等病理特征比较,差异均无统计学意义。尚需进一步随访明确甲状腺疾病对乳腺癌患者预后的影响。
第二部分伴随甲状腺疾病的乳腺癌患者中医证型分布研究
目的
探讨同时伴随甲状腺疾病的乳腺癌患者中医证型的分布情况,并进一步比较伴发甲状腺疾病组和甲状腺正常组的乳腺癌中医证型的差异,初探甲状腺疾病是否影响乳腺癌中医证型的分布。
方法
乳腺癌患者入院时填写症状调查表,分别统计伴随甲状腺疾病的乳腺癌患者及甲状腺正常的乳腺癌患者的中医证型分布情况及症状分级量化值。
结果
伴随甲状腺疾病的乳腺癌组中,肝郁脾虚证占50%,其次是肾阴虚(19.35%)、血瘀证(16.13%)、肾阳虚(14.52%)。甲状腺正常的乳腺癌组中,肝郁脾虚证占57.89%,其次是血瘀证(21.05%)、肾阴虚(10.53%)、肾阳虚(10.53%)。两组之间的各证型分布,差异均无统计学意义(P>0.05)。两组乳腺癌患者各中医证型的症状分级量化值比较,差异均无统计学意义(P>0.05)。
结论
甲状腺疾病对乳腺癌患者的中医证型分布无明显影响。两组患者的症状分级量化值比较,无明显差异。
第三部分昆布多糖对乳腺癌MCF-7细胞钠碘转运体的基因和蛋白表达及摄碘率的影响
目的
探讨掌状昆布提取物昆布多糖对乳腺癌细胞株MCF-7钠碘转运体(NIS)基因、蛋白表达和摄碘功能的影响,为昆布多糖辅助同位素早期诊断和治疗乳腺癌提供理论依据。
方法
对乳腺癌细胞株(MCF-7)进行培养,分别给予不同浓度的昆布多糖(0,10ug/mL, 50ug/mL,100ug/mL,200ug/mL),分别孵育24小时、48小时及72小时。采用Real-timePCR法、Western blot法检测细胞中NIS的mRNA和蛋白表达,并用125I测定细胞的摄碘能力。
结果
不同浓度的昆布多糖刺激乳腺癌细胞(MCF-7) 24h后,NISmRNA和蛋白的表达与空白对照组比较均增加,差异有统计学意义(P<0.05),并与刺激浓度呈正比,各组间比较中,除100ug/ml组和200ug/ml组之间无明显差异(P>0.05),余组间比较,差异均有统计学意义(P<0.05)；不同浓度的昆布多糖刺激乳腺癌细胞(MCF-7) 48h后,NISmRNA和蛋白的表达与空白对照组比较均增加,差异有统计学意义(P<0.05),且与刺激浓度呈正比,各组间比较,差异均有统计学意义(P<0.05)；不同浓度的昆布多糖刺激乳腺癌细胞(MCF-7) 72h后,NISmRNA和蛋白的表达与空白对照组比较均增加,差异有统计学意义(P<0.05),提示与刺激浓度呈正比,各组间比较中,除100ug/ml组和200ug/ml组之间无明显差异(P>0.05),余组间比较,差异均有统计学意义(P<0.05)。不同浓度的昆布多糖刺激MCF-7细胞48h后,与空白对照组比较,10ug/ml组的摄碘率无明显增加,差异无统计学意义(P>0.05),随着浓度增加,摄碘率却显示明显增加,差异均有统计学意义(P<0.05),提示与刺激浓度成正比。余组间比较,差异均有统计学意义(P<0.05)。
结论
不同浓度的昆布多糖刺激乳腺癌细胞(MCF-7),使NISmRNA和蛋白的表达均增加,且与刺激浓度呈正比。昆布多糖可能通过调节乳腺癌细胞NIS基因和蛋白的表达而改善细胞摄碘能力。
Background and objective
Breast cancer is one of the most common malignant tumors which seriously threaten the health of women. The incidence and mortality of breast cancer are rank the first among the famale malignancy tumors. Especially in some economic flourishing regions and big city in our country, the incidence was resided the first female malignant tumor. Breast and thyroid belong to organs which are sensitive to pituitrin. The change of endocrine can leads to gland diseases. Breast cancer cells which still have normal function of hormone receptor grow depending on original hormones. Thyroid hormones promote the development and atomization of normal breast tissues. Thyroid hormones which can directly control the proliferation of cells change the metabolism of anterior pituitary, germen hormones and carcinogen by the shortage and excessive of its content.Thus, the thyroid hormones may promote the growth of tumor cells and also may suppress the development of tumor cells. Thyroid hormone receptor and Thyroid stimulating hormone receptor expresses in the breast tissues, estrogen effects developments physiology and pathology of thyroid. We discuss the relationship between breast cancer and thyroid diseases and realize whether thyroid diseases effect the progonosis of breast cancer.
According to " The standard of efficacy of TCM sympotomes " pubished by State Administration of Traditional Chinese Medicine (ZY/T001.2-94), the sympotomes of breast cancer include three categories:Stagnation of liver-qi and accumulation of phlegm, Incoordination of the thoroughfare and conception vessels, Excessive toxin due to deficient qi. Thyroid diseases which belong to " goiter " in TCM is relevance of emotion, diet and natural enviroment and dimate. Stagnation of liver-qi, disharmony of the spleen, imbalance of zang-fu and retardent of meridians and collaterals which lead to qi stagnation, blood stasis and accumulation of phlegm which coagulate the neck. In addition, it is relevance with deficiency of liver and kidney and extrnal infection.The goiter and breast cancer are both relate to kidney, liver and spleen. Thus, they have the relevance in the pathogenesis of TCM theory. We discuss the distribution of breast cancer patients having thyroid diseases and further study thyroid diseases whether influenced its distribution.
The sodium-iodide symporter (NIS) which is an integral membrane protein of thyroid follicular cells transports active iodide from vessels into cells through exchange Na+ and K+. It transports active iodide necessary for thyroid hormone synthesis. Accordingly, radioiodines are used for the diagnosis and treatment of various thyroid diseases. Most differentiated thyroid carcinomas retain NIS protein activity. This provides the basis for the use of radioiodine in the detection and therapy of thyroid cancer. Moreover, iodide also accumulates in the lactating mammary gland and is secreted into milk. Like thyroid cancers, it is possible that breast cancers express the NIS gene and protein. Several investigators have reported the expression of NIS protein and the NIS gene in various cases of human breast cancer. There is a possibility of being able to use NIS and radionuclide for the detection and treatment of breast cancer. Basal NIS gene expression is detected in about 85% breast cancer specimens, but the fraction with functional iodide transport is relatively low. The radioiodine is difficult to treat breast cancer. Retinoic acid has been used to stimulate NIS expression in both thyroid and breast cancer. Agents that promote tumor differentiation, or directly stimulate NIS gene expression, may result in iodine concentration in 'scan-negative'thyroid cancer and some breast cancer. Lactogenic hormones, estrogen, cAMP stimulus, glucocorticoid can stimulate NIS expression and increase radioiodide uptake.
Thallus japonica which is Laminarin japonica Aresch has the effect of softening hardness to dissipate stagnation and disinhibiting water to draining heat. Thallus japonica is rich in iodide which maintains normal function of thyroid and breast tissue.It has lots of active ingredients which relate to its polysaccharide ingredients. Laminarin which is aβ-1,3 glucosan polymer can activate macrophagocyte and produce cytotoxicity in order to restrain the proliferati on of tumor cells. In addition, it can suppress tumor angiogenesis to control tumor growth. We research the effect of Laminarin to NIS gene and protein expression of MCF-7 cells and discuss the relationship between iodide uptake and NIS gene and protein expression.
Part I The clinic research of the relationship between breast cancer and thyroid pathology
Objective
The aim of the study was to comfirm the incidence of the thyroid diseases among breast cancer patients and discuss whether thyroid diseases effect the prognosis of breast cancer patients.
Methods
Our prospective open study was conducted on 100 consecutive patients operated for breast carcinoma. As a control group,100 individuals with normal breast examination, who did not have any known malignancy and/or thyroid disease, were included in the study. We aimed to identify the occurrence of thyroid pathologies, thyroid volume, the positive rate of TPOAb and TgAb and the number of TT3、TT4、FT3、FT4、TSH、TPOAb、TgAb in both groups to compare the ultrasound and the laboratory features of thyroid disease (TT3、TT4、FT3、FT4、TSH、TPOAb、TgAb) and breast carcinoma in an attempt to contribute to the studies investigating the relationship between these two entities.In addition,we also identified the pathology and biology features of breast cancer patients with/without thyroid diseases. We definited the baseline features such as age, menstruation and BMI of two groups.
Results
The thyroid volumes of breast cancer patients and the control group did not differ significantly (P>0.05). When breast carcinoma patients were compared with the control group, thyroid pathology were found to be significa-ntly high in patients with breast cancer(62% vs 38%, P<0.05). There was no statistically significant difference between the two groups with respect to TPOAb、TgAb、TT3、TT4、FT3、FT4、TSH levels (P>0.05). Multiple nodular and nodular goiter thyroid pathologies were significantly higher in the breast cancer group when compared to the control group(P<0.05). There was no statistically significant difference between the two groups with respect to single nodular,adenoma cystadenoma, cystis thyroid pathologies and hyperthyroidism, hypothyroidism, subclinical hypothyroidism, subclinical hyperthyroidism, Hashimoto's thyroiditis(P>0.05). The incidence of TPOAb and TgAb positive are significantly higher in the breast cancer group when compared to the control group (P>0.05). In breast cancer patients with thyroid pathology, the incidence of HER-2 positive and Ki-67>30% were significantly more compared to the patients without thyroid disease(P<0.05). There was no significant relationship between other pathology features such as lymph nodes, the classification of histology, the stage of pathology, cancer embolus in vessel, progestational hormone receptor and estrogenic hormone receptor of the breast cancer patients and the presence of thyroid pathology (P>0.05). There was no statistically significant difference between the baseline features such as age, menstruation and BMI(P>0.05).
Conclusion
In conclusion, the frequency of thyroid pathology is higher in breast cancer patients compared to controls indicating a relationship between breast carcinoma and thyroid pathology. Our study shows that breast cancer patients accompany with thyroid morphology changes such as multiple nodular and nodular goiter. The incidence of TPOAb and TgAb positive are significant-ly higher in the breast cancer group, it is indicated that breast cancer may be relevance to autoimmune thyroid diseases. Although the incidence of HER-2 positive and Ki-67>30% are higher in breast cancer patients with thyroid thyroid pathology, there was no significant relationship between other pathology features such as lymph nodes, the classification of histolog-y, the stage of pathology, cancer embolus in vessel, progestational hormone receptor and estrogenic hormone receptor of the breast cancer patients and the presence of thyroid pathology, we need further studies are needed to investigate the prognosis and survival of breast cancer patients in the presence of thyroid pathology. PartⅡResearch on the d i str i but i on of TCM syndromes i n breast cancer patients with thyroid pathology Object ive
To study the distribution of TCM syndromes in breast cancer patients with thyroid pathology and disscuss thyroid pathology whether influences the the distribution of TCM syndromes in breast cancer. Methods
When breast cancer patients were hospitalized, the questionnaire was written in time. Through satatistic analysis, it is confirmed that the distribution of TCM syndromes in breast cancer patients with thyroid pathology and control group.
Results
In breast cancer patients with thyroid pathology, Stagnation of liver-qi and deficiency of spleen occupied 50%, deficiency of kidney-yin occupied 19.35%, blood stasis occupied 16.13%, deficiency of kidney-yang occupied 14.52%. In the control group, Stagnation of liver-qi and deficiency of spleen occupied 57.89%, deficiency of kidney-yin occupied 10.53%, blood stasis occupied 21.05%, deficiency of kidney-yang occupied 10.53%. There was no statistically significant difference between the two groups with respect to the distribution and the grading numbers of TCM syndromes (P>0.05).
Conclusion
Thyroid pathology did not effect the distribution of TCM syndromes in breast cancer patients. There was no statistically significant difference between the two groups with respect to the grading numbers of TCM syndromes.
PartⅢThe effect of Laminar in on the expression of NIS gene and protein expression and rate of iodide uptake in breast cell(MCF-7).
Objective
To investigate the effect of Laminarin on the expression of gene and protein of NIS and the relationship between NIS expression and the ability of iodide uptake in breast cancer cell.
Methods
The breast cancer cell line(MCF-7) was cultured with different concentrations of Laminarin(0, 10ug/mL,50ug/mL,100ug/mL,200ug/mL). NTS mRNA and protein in cultured breast cancer cells was determined by Real-time PCR and Western blot after 24h,48h,72h. The activity of iodide uptake was determined by 125I uptake rate. Results
When compared with blank control group, NIS gene expression and prote in expression were enhanced by Laminarin in dose-dependent manner after s timulating 24h (P<0.05). There was no statistically significant differen ce between 100ug/ml and 200ug/ml after stimulating 24h(P>0.05). Compared among other groups, they all have statistically significant diffe rence (P<0.05). When compared with blank control group, NIS gene expressi on and protein expression were enhanced by Laminarin in dose-dependent ma nner after stimulating 48h(P<0.05). Compared among groups, they allhave st atistically significant difference (P<0.05). When compared withblank cont rol group, NIS gene expression and protein expression were enh-anced by La minarin in dose-dependent manner after stimulating 72h(P<0.05). There was no statistically significant difference between 100ug/ml and 200ug/ml af ter stimulating 72h(P>0.05). Compared among other groups, they all have st atistically significant difference(P<0.05). The activity of iodide uptak e had been found to be increased by Laminarin in dose-dependent manner(P <0.05). There was no statistically significant diffe-rence between Oug/ml and 10ug/ml (P>0.05).
Conclusion
NIS gene expression and protein expression were enhanced by Laminari-n in dose-dependent manner. The activity of iodide uptake had been found to be increased by Laminarin which may be attribute to enhance the NIS gene experessin and protein expression.
乳腺癌是严害威胁妇女心身健康的恶性肿瘤,在女性恶性肿瘤中其发病率和死亡率均居前列。在我国一些大城市中乳腺癌的发病率逐年递增,已跃居女性恶性肿瘤的首位。乳腺与甲状腺同属于垂体激素的靶器官,内分泌功能的变化与腺体疾病的发生发展有着密切的关系,乳腺组织的细胞癌变后仍具有激素受体功能,其原来所依赖的激素仍然调节着肿瘤细胞的生长。甲状腺激素在正常乳腺的发育和分化过程中起着促进作用。甲状腺激素可直接调控机体的生长和细胞的增殖,其含量的不足或过量均可改变垂体前叶和靶器官激素及化学致癌因子的代谢,因此认为乳腺癌的病程演进可能会受到甲状腺激素含量高低不同的影响。甲状腺激素对乳腺癌的作用仍不明,有可能既是肿瘤细胞形成的促进因子,也是对抗肿瘤细胞形成和生长的保护因子。研究发现促甲状腺激素受体和甲状腺激素受体在乳腺组织中有表达,反过来雌激素也影响着甲状腺的发育、生理及病理过程。本研究探讨甲状腺疾病与乳腺癌之间的相关性,了解甲状腺疾病对乳腺癌患者预后的影响。
根据国家中医药管理局颁布的《中医病症疗效标准》ZY/T001.2-94将乳腺癌分为3型：肝郁痰凝证、冲任失调证、正虚毒炽证。而甲状腺疾病则属于中医“瘿病”范畴,瘿病的发生主要与情志内伤、饮食及水土失宜有关。在致病因素作用下,肝郁不舒,脾失健运,脏腑失调,经络阻滞,导致气滞、血瘀、痰凝结于颈部而发病。此外,其发病与肝肾不足、六淫外感也有一定关系。常见证候有肝气郁结、肝郁脾虚、肝肾阴虚、肝阳上亢等。甲状腺疾病和乳腺癌的发生均与肝、脾、肾三脏有密切关系,可见两者的病因病机在中医理论的角度也存在相关性。本研究通过调查伴随甲状腺疾病的乳腺癌患者和甲状腺正常的乳腺癌患者的临床症状及症状分级量化值,探讨伴随甲状腺疾病的乳腺癌患者的证型分布情况,了解甲状腺疾病是否影响乳腺癌患者的中医证型分布。
钠碘转运体(Na+/I-Symporter, NIS)是一种糖化膜蛋白,即“碘泵”,其功能主要是借助于钠/钾交换而产生的细胞内外钠离子浓度梯度来转运血液内活性碘进入细胞,使胞内碘含量浓聚为血浆的20-100倍。NIS浓聚碘是甲状腺激素生物合成、诊断甲状腺核素显像以及甲亢、甲状腺肿瘤放射性碘治疗的基础。已经证实哺乳期的乳腺导管细胞上表达NIS并能浓聚碘,研究发现约85%的ER阳性乳腺癌及其转移组织细胞表面存在大量NIS,可主动将血液中的碘转运到乳腺癌组织,使其碘浓聚远高于正常组织,并发现87%的浸润性乳腺癌和83%的导管内癌表达NIS,而正常乳腺组织无NIS表达,但乳腺癌组织摄碘能力并没因为NIS表达的增加而增加。用放射性碘治疗恶性肿瘤的是肿瘤综合治疗的方法之一,而放射性碘发挥杀伤肿瘤细胞效应的基础是肿瘤细胞必须具有摄碘能力,但乳腺癌组织摄取碘的能力较低,使放射性碘治疗难以发挥效应。研究发现催乳激素、雌激素、cAMP刺激物、维甲酸类,糖皮质激素通过增加NIS基因表达以增强乳腺癌细胞的碘摄取。
昆布(Thallus japonica)是大叶藻科植物大叶藻的全草,俗称“海带”,具有软坚散结、利水泄热等功效,昆布是一种含碘量很高的海藻,碘对维持甲状腺与乳腺组织细胞的正常功能具有重要作用。昆布中含有很多活性成分,它的大部分活性成分与它的多糖成分关系密切,目前对昆布多糖的研究越来越受到重视。昆布多糖是一种β-1,3葡聚糖的聚合物,可以通过激活巨噬细胞,产生细胞毒性作用,抑制肿瘤细胞增殖而杀伤肿瘤细胞；也可以通过抑制肿瘤血管生成而抑制肿瘤生长。本课题主要研究昆布多糖对乳腺癌细胞(MCF-7) NIS基因和蛋白表达的影响,并探讨其与细胞摄碘功能之间的关系。
第一部分乳腺癌与甲状腺疾病关系的临床研究
目的
调查乳腺癌患者中甲状腺疾病的发病率,通过与对照组中甲状腺疾病的发病率比较,初探乳腺癌与甲状腺疾病之间的关系；初步了解甲状腺疾病对乳腺癌患者预后的影响。
方法
采用临床非随机对照研究的方法,选取我院可手术乳腺癌患者100例作为乳腺癌组,选取体检中心体检者100例作为对照组,分别接受甲状腺彩超、甲状腺抗体2项(TPOAb、TgAb)及甲功5项(TT3、TT4、FT3、FT4、TSH)检查,分别统计两组患者的TT3、TT4、FT3、FT4、TSH值,TPOAb及TgAb阳性率,甲状腺左右叶体积,甲状腺疾病的发病率。分别统计伴随甲状腺疾病的乳腺癌患者及甲状腺正常的乳腺癌患者的病理及生物学特征。分别统计两组患者的年龄、月经状况、体重指数(BMI)等基线特征。
结果
乳腺癌组和对照组的甲状腺左右叶体积大小比较,差异无统计学意义(P>0.05)；两组患者甲状腺疾病的总发病率分别为62%和38%,差异有统计学意义(P<0.05)；两组患者之间的TT3、TT4、FT3、FT4、TSH值比较,差异均无统计学意义(P>0.05)；两组患者之间的甲状腺单发结节、甲状腺腺瘤、甲状腺囊腺瘤、甲状腺囊肿、桥本氏甲状腺炎、甲亢、甲减、亚临床甲亢、亚临床甲减的发病率比较,差异均无统计学意义(P>0.05)；与对照组相比较,乳腺癌组的甲状腺多发结节、结节性甲状腺肿的发病率高,差异有统计学意义(P<0.05)；与对照组比较,乳腺癌组的TPOAb和TgAb性的发病率高,差异有统计学意义(P<0.05)；与甲状腺正常的乳腺癌患者相比较,伴随甲状腺疾病的乳腺癌患者的Her-2阳性的表达率高,Ki-67>30%的增殖率增高,差异均有统计学意义(P<0.05)；两组的区域淋巴结、组织学分级、病理分期、脉管癌栓、雌激素受体、孕激素受体等病理特征比较,差异均无统计学意义(P>0.05)。两组患者的年龄、月经状况、BMI等基线特征比较,差异均无统计学意义(P>0.05)；
结论
乳腺癌组的甲状腺疾病总发病率高于对照组；乳腺癌患者的甲状腺多发结节、结节性甲状腺肿的发病率较高,提示乳腺癌患者多伴发甲状腺病理形态方面的改变；乳腺癌组TPOAb及TgAb阝日性率高,提示乳腺癌与自身免疫性甲状腺疾病可能相关；伴随甲状腺疾病的乳腺癌患者Her-2阳性的表达率较高,Ki-67增殖率较高,提示可能预后较差；而两组的区域淋巴结、组织学分级、病理分期、脉管癌栓、雌激素受体、孕激素受体等病理特征比较,差异均无统计学意义。尚需进一步随访明确甲状腺疾病对乳腺癌患者预后的影响。
第二部分伴随甲状腺疾病的乳腺癌患者中医证型分布研究
目的
探讨同时伴随甲状腺疾病的乳腺癌患者中医证型的分布情况,并进一步比较伴发甲状腺疾病组和甲状腺正常组的乳腺癌中医证型的差异,初探甲状腺疾病是否影响乳腺癌中医证型的分布。
方法
乳腺癌患者入院时填写症状调查表,分别统计伴随甲状腺疾病的乳腺癌患者及甲状腺正常的乳腺癌患者的中医证型分布情况及症状分级量化值。
结果
伴随甲状腺疾病的乳腺癌组中,肝郁脾虚证占50%,其次是肾阴虚(19.35%)、血瘀证(16.13%)、肾阳虚(14.52%)。甲状腺正常的乳腺癌组中,肝郁脾虚证占57.89%,其次是血瘀证(21.05%)、肾阴虚(10.53%)、肾阳虚(10.53%)。两组之间的各证型分布,差异均无统计学意义(P>0.05)。两组乳腺癌患者各中医证型的症状分级量化值比较,差异均无统计学意义(P>0.05)。
结论
甲状腺疾病对乳腺癌患者的中医证型分布无明显影响。两组患者的症状分级量化值比较,无明显差异。
第三部分昆布多糖对乳腺癌MCF-7细胞钠碘转运体的基因和蛋白表达及摄碘率的影响
目的
探讨掌状昆布提取物昆布多糖对乳腺癌细胞株MCF-7钠碘转运体(NIS)基因、蛋白表达和摄碘功能的影响,为昆布多糖辅助同位素早期诊断和治疗乳腺癌提供理论依据。
方法
对乳腺癌细胞株(MCF-7)进行培养,分别给予不同浓度的昆布多糖(0,10ug/mL, 50ug/mL,100ug/mL,200ug/mL),分别孵育24小时、48小时及72小时。采用Real-timePCR法、Western blot法检测细胞中NIS的mRNA和蛋白表达,并用125I测定细胞的摄碘能力。
结果
不同浓度的昆布多糖刺激乳腺癌细胞(MCF-7) 24h后,NISmRNA和蛋白的表达与空白对照组比较均增加,差异有统计学意义(P<0.05),并与刺激浓度呈正比,各组间比较中,除100ug/ml组和200ug/ml组之间无明显差异(P>0.05),余组间比较,差异均有统计学意义(P<0.05)；不同浓度的昆布多糖刺激乳腺癌细胞(MCF-7) 48h后,NISmRNA和蛋白的表达与空白对照组比较均增加,差异有统计学意义(P<0.05),且与刺激浓度呈正比,各组间比较,差异均有统计学意义(P<0.05)；不同浓度的昆布多糖刺激乳腺癌细胞(MCF-7) 72h后,NISmRNA和蛋白的表达与空白对照组比较均增加,差异有统计学意义(P<0.05),提示与刺激浓度呈正比,各组间比较中,除100ug/ml组和200ug/ml组之间无明显差异(P>0.05),余组间比较,差异均有统计学意义(P<0.05)。不同浓度的昆布多糖刺激MCF-7细胞48h后,与空白对照组比较,10ug/ml组的摄碘率无明显增加,差异无统计学意义(P>0.05),随着浓度增加,摄碘率却显示明显增加,差异均有统计学意义(P<0.05),提示与刺激浓度成正比。余组间比较,差异均有统计学意义(P<0.05)。
结论
不同浓度的昆布多糖刺激乳腺癌细胞(MCF-7),使NISmRNA和蛋白的表达均增加,且与刺激浓度呈正比。昆布多糖可能通过调节乳腺癌细胞NIS基因和蛋白的表达而改善细胞摄碘能力。
Background and objective
Breast cancer is one of the most common malignant tumors which seriously threaten the health of women. The incidence and mortality of breast cancer are rank the first among the famale malignancy tumors. Especially in some economic flourishing regions and big city in our country, the incidence was resided the first female malignant tumor. Breast and thyroid belong to organs which are sensitive to pituitrin. The change of endocrine can leads to gland diseases. Breast cancer cells which still have normal function of hormone receptor grow depending on original hormones. Thyroid hormones promote the development and atomization of normal breast tissues. Thyroid hormones which can directly control the proliferation of cells change the metabolism of anterior pituitary, germen hormones and carcinogen by the shortage and excessive of its content.Thus, the thyroid hormones may promote the growth of tumor cells and also may suppress the development of tumor cells. Thyroid hormone receptor and Thyroid stimulating hormone receptor expresses in the breast tissues, estrogen effects developments physiology and pathology of thyroid. We discuss the relationship between breast cancer and thyroid diseases and realize whether thyroid diseases effect the progonosis of breast cancer.
According to " The standard of efficacy of TCM sympotomes " pubished by State Administration of Traditional Chinese Medicine (ZY/T001.2-94), the sympotomes of breast cancer include three categories:Stagnation of liver-qi and accumulation of phlegm, Incoordination of the thoroughfare and conception vessels, Excessive toxin due to deficient qi. Thyroid diseases which belong to " goiter " in TCM is relevance of emotion, diet and natural enviroment and dimate. Stagnation of liver-qi, disharmony of the spleen, imbalance of zang-fu and retardent of meridians and collaterals which lead to qi stagnation, blood stasis and accumulation of phlegm which coagulate the neck. In addition, it is relevance with deficiency of liver and kidney and extrnal infection.The goiter and breast cancer are both relate to kidney, liver and spleen. Thus, they have the relevance in the pathogenesis of TCM theory. We discuss the distribution of breast cancer patients having thyroid diseases and further study thyroid diseases whether influenced its distribution.
The sodium-iodide symporter (NIS) which is an integral membrane protein of thyroid follicular cells transports active iodide from vessels into cells through exchange Na+ and K+. It transports active iodide necessary for thyroid hormone synthesis. Accordingly, radioiodines are used for the diagnosis and treatment of various thyroid diseases. Most differentiated thyroid carcinomas retain NIS protein activity. This provides the basis for the use of radioiodine in the detection and therapy of thyroid cancer. Moreover, iodide also accumulates in the lactating mammary gland and is secreted into milk. Like thyroid cancers, it is possible that breast cancers express the NIS gene and protein. Several investigators have reported the expression of NIS protein and the NIS gene in various cases of human breast cancer. There is a possibility of being able to use NIS and radionuclide for the detection and treatment of breast cancer. Basal NIS gene expression is detected in about 85% breast cancer specimens, but the fraction with functional iodide transport is relatively low. The radioiodine is difficult to treat breast cancer. Retinoic acid has been used to stimulate NIS expression in both thyroid and breast cancer. Agents that promote tumor differentiation, or directly stimulate NIS gene expression, may result in iodine concentration in 'scan-negative'thyroid cancer and some breast cancer. Lactogenic hormones, estrogen, cAMP stimulus, glucocorticoid can stimulate NIS expression and increase radioiodide uptake.
Thallus japonica which is Laminarin japonica Aresch has the effect of softening hardness to dissipate stagnation and disinhibiting water to draining heat. Thallus japonica is rich in iodide which maintains normal function of thyroid and breast tissue.It has lots of active ingredients which relate to its polysaccharide ingredients. Laminarin which is aβ-1,3 glucosan polymer can activate macrophagocyte and produce cytotoxicity in order to restrain the proliferati on of tumor cells. In addition, it can suppress tumor angiogenesis to control tumor growth. We research the effect of Laminarin to NIS gene and protein expression of MCF-7 cells and discuss the relationship between iodide uptake and NIS gene and protein expression.
Part I The clinic research of the relationship between breast cancer and thyroid pathology
Objective
The aim of the study was to comfirm the incidence of the thyroid diseases among breast cancer patients and discuss whether thyroid diseases effect the prognosis of breast cancer patients.
Methods
Our prospective open study was conducted on 100 consecutive patients operated for breast carcinoma. As a control group,100 individuals with normal breast examination, who did not have any known malignancy and/or thyroid disease, were included in the study. We aimed to identify the occurrence of thyroid pathologies, thyroid volume, the positive rate of TPOAb and TgAb and the number of TT3、TT4、FT3、FT4、TSH、TPOAb、TgAb in both groups to compare the ultrasound and the laboratory features of thyroid disease (TT3、TT4、FT3、FT4、TSH、TPOAb、TgAb) and breast carcinoma in an attempt to contribute to the studies investigating the relationship between these two entities.In addition,we also identified the pathology and biology features of breast cancer patients with/without thyroid diseases. We definited the baseline features such as age, menstruation and BMI of two groups.
Results
The thyroid volumes of breast cancer patients and the control group did not differ significantly (P>0.05). When breast carcinoma patients were compared with the control group, thyroid pathology were found to be significa-ntly high in patients with breast cancer(62% vs 38%, P<0.05). There was no statistically significant difference between the two groups with respect to TPOAb、TgAb、TT3、TT4、FT3、FT4、TSH levels (P>0.05). Multiple nodular and nodular goiter thyroid pathologies were significantly higher in the breast cancer group when compared to the control group(P<0.05). There was no statistically significant difference between the two groups with respect to single nodular,adenoma cystadenoma, cystis thyroid pathologies and hyperthyroidism, hypothyroidism, subclinical hypothyroidism, subclinical hyperthyroidism, Hashimoto's thyroiditis(P>0.05). The incidence of TPOAb and TgAb positive are significantly higher in the breast cancer group when compared to the control group (P>0.05). In breast cancer patients with thyroid pathology, the incidence of HER-2 positive and Ki-67>30% were significantly more compared to the patients without thyroid disease(P<0.05). There was no significant relationship between other pathology features such as lymph nodes, the classification of histology, the stage of pathology, cancer embolus in vessel, progestational hormone receptor and estrogenic hormone receptor of the breast cancer patients and the presence of thyroid pathology (P>0.05). There was no statistically significant difference between the baseline features such as age, menstruation and BMI(P>0.05).
Conclusion
In conclusion, the frequency of thyroid pathology is higher in breast cancer patients compared to controls indicating a relationship between breast carcinoma and thyroid pathology. Our study shows that breast cancer patients accompany with thyroid morphology changes such as multiple nodular and nodular goiter. The incidence of TPOAb and TgAb positive are significant-ly higher in the breast cancer group, it is indicated that breast cancer may be relevance to autoimmune thyroid diseases. Although the incidence of HER-2 positive and Ki-67>30% are higher in breast cancer patients with thyroid thyroid pathology, there was no significant relationship between other pathology features such as lymph nodes, the classification of histolog-y, the stage of pathology, cancer embolus in vessel, progestational hormone receptor and estrogenic hormone receptor of the breast cancer patients and the presence of thyroid pathology, we need further studies are needed to investigate the prognosis and survival of breast cancer patients in the presence of thyroid pathology. PartⅡResearch on the d i str i but i on of TCM syndromes i n breast cancer patients with thyroid pathology Object ive
To study the distribution of TCM syndromes in breast cancer patients with thyroid pathology and disscuss thyroid pathology whether influences the the distribution of TCM syndromes in breast cancer. Methods
When breast cancer patients were hospitalized, the questionnaire was written in time. Through satatistic analysis, it is confirmed that the distribution of TCM syndromes in breast cancer patients with thyroid pathology and control group.
Results
In breast cancer patients with thyroid pathology, Stagnation of liver-qi and deficiency of spleen occupied 50%, deficiency of kidney-yin occupied 19.35%, blood stasis occupied 16.13%, deficiency of kidney-yang occupied 14.52%. In the control group, Stagnation of liver-qi and deficiency of spleen occupied 57.89%, deficiency of kidney-yin occupied 10.53%, blood stasis occupied 21.05%, deficiency of kidney-yang occupied 10.53%. There was no statistically significant difference between the two groups with respect to the distribution and the grading numbers of TCM syndromes (P>0.05).
Conclusion
Thyroid pathology did not effect the distribution of TCM syndromes in breast cancer patients. There was no statistically significant difference between the two groups with respect to the grading numbers of TCM syndromes.
PartⅢThe effect of Laminar in on the expression of NIS gene and protein expression and rate of iodide uptake in breast cell(MCF-7).
Objective
To investigate the effect of Laminarin on the expression of gene and protein of NIS and the relationship between NIS expression and the ability of iodide uptake in breast cancer cell.
Methods
The breast cancer cell line(MCF-7) was cultured with different concentrations of Laminarin(0, 10ug/mL,50ug/mL,100ug/mL,200ug/mL). NTS mRNA and protein in cultured breast cancer cells was determined by Real-time PCR and Western blot after 24h,48h,72h. The activity of iodide uptake was determined by 125I uptake rate. Results
When compared with blank control group, NIS gene expression and prote in expression were enhanced by Laminarin in dose-dependent manner after s timulating 24h (P<0.05). There was no statistically significant differen ce between 100ug/ml and 200ug/ml after stimulating 24h(P>0.05). Compared among other groups, they all have statistically significant diffe rence (P<0.05). When compared with blank control group, NIS gene expressi on and protein expression were enhanced by Laminarin in dose-dependent ma nner after stimulating 48h(P<0.05). Compared among groups, they allhave st atistically significant difference (P<0.05). When compared withblank cont rol group, NIS gene expression and protein expression were enh-anced by La minarin in dose-dependent manner after stimulating 72h(P<0.05). There was no statistically significant difference between 100ug/ml and 200ug/ml af ter stimulating 72h(P>0.05). Compared among other groups, they all have st atistically significant difference(P<0.05). The activity of iodide uptak e had been found to be increased by Laminarin in dose-dependent manner(P <0.05). There was no statistically significant diffe-rence between Oug/ml and 10ug/ml (P>0.05).
Conclusion
NIS gene expression and protein expression were enhanced by Laminari-n in dose-dependent manner. The activity of iodide uptake had been found to be increased by Laminarin which may be attribute to enhance the NIS gene experessin and protein expression.
引文
[1]Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics,2002. CA Cancer J Clin,2005; 55(2):74-108.
[2]Parkin DM, Fernandez LM. Use of statistics to assess the global burden of breast cancer. Breast J,2006; 12 Suppll:S70-S80.
[3]Lee JH, Yim SH, Won YJ, et al. Population-based breast cancer statistics in Korea during 1993-2002:incidence, mortality and survival. J Korean Med Sci,2007; 22 Suppl:S11-S16.
[4]Cancer incidence in five continents. Volume Ⅷ. IARC Sci Publ,2002; 7(155):1-781.
[5]王庆生,林晓萍.中国乳腺癌流行病学研究.2000全国肿瘤学术大会论文集,2000：308.
[6]罗学林.乳腺癌与甲状腺激素.国外医学肿瘤学分册,1981；8(5)：213-214.
[7]唐荣德,黄小兵,郭爱群等.江门市新会区甲状腺功能检测结果的调查分析.热带医学杂志,2005；5(6)：846-851.
[8]刘超,武晓泓.钠/碘转运体.国外医学内分泌分册,2000；20(2)：59-62.
[9]Cho JY, Leveille R, Kao R, et al. Hormonal regulation of radioiodide uptake activity and Na+/I-symporter expression in mammary glands. J Clin Endocrinol Metab,2000; 85(8):2936-2943.
[10]Goldman MB. Thyroid diseases and breast cancer. Epidemiol Rev,1990; 12:16-28.
[11]Zhou-Li F, Albaladejo V, Pharaboz MOJ, et al. Antiestrogens prevent the stimulatory effects of L-triiodothyronine on cell proliferation. Endocrinology,1992; 130:1145-1152.
[12]Oh HJ, Chung JK, Kang JH, et al. The relationship between expression of the sodium/iodide symporter gene and the status of hormoal receptors in human breast cancer tissue,2005; 37(4):247-250.
[13]Tazebay UH, Wapnir H, Levy 0, et al. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med,2000; 6(8):871-878.
[14]Smyth PP. The thyroid, iodine and breast cancer. Breast Cancer Res,2003; 5(5):235-238.
[15]Teas J, Hurley TG, Hebert JR, et al. Dietary seaweed modifies estrogen and phytoestrogen metabolism in healthy postmenopausal women. J Nutr,2009; 139(5):939-944.
[16]Yang YJ, Nam SJ, Kong G, et al. A case-control study on seaweed consumption and the risk of breast cancer. Br J Nutr,2010; 103(9):1345-1353.
[17]Haroun-Bouhedja F, Lindenmeyer F, Lu H, et al. In vitro effects of fucans on MDA-MB231 tumor cell adhesion and invasion. Anticancer Res,2002; 22(4):2285-2292.
[18]Liu JM, Bignon J, Haroun-Bouhedja F, et al. Inhibitory effect of fucoidan on the adhesion of adenocarcinoma cells to fibronectin. Anticancer Res, 2005; 25(3B):2129-2133.
[19]Funahashi H, Imai T, Tanaka Y. Wakame seaweed suppresses the prolifer-ation of 7,12-dimethylbenz(a)-anthracene-induced mammary tumors in rats. Jpn J Cancer Res,1999; 90(9):922-927.
[20]Shrivastava A, Tiwan M, Sinha RA, et al. Molecular iodine induces caspase-independent apopotosis in human breast carcinoma cells involving the mitochondria-mediated pathway. J Biol Chem,2006; 281 (28):19762-19771.
[21]Tang HY, Lin HY, Zhang S, et al. Thyroid hormone causes mitogen activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor. Endocrinology,2004; 145(7):3265-3272.
[22]Cestari SH, Figueiredo NB, Conde SJ, et al. Influence of estradiol and triiodothyronine T3 on breast cancer cell lines proliferation and expression of estrogen and thyroid hormone receptors. Arq Bras Endocrinol Metabol,2009; 53(7):859-864.
[23]Gonzalez-Sancho JM, Alvarez-Dolado M, Caelles C, et al. Inhibition of tenascin-C expression in mammary epithelial cells by thyroid hormone. Mol Carcinog,1999; 24(2):99-107.
[24]Gago-Dominguez M, Castelao JE. Role of lipid peroxidation, and oxidative stress in the association between thyroid diseases and breast cancer. Crit Rev Oncol Hematol,2008; 68(2):107-114.
[25]Tosovic A, Bondeson AG, Bondeson L, et al. Prospectively measured triiodothyronine levels are positively associated with breast cancer risk in postmenopausal women. Breast Cancer Res,2010; 12(3):R33.
[26]Saraiva PP, Figueiredo NB, Padovani CR.et al. Profile of thyroid hormones in breast cancer patients. Braz J Med Biol Res,2005; 38 (5):761-765.
[27]Gonzalez-Sancho JM, Figueroa A, Lopez-Barahona M, et al. Inhibition of proliferation and expression of T1 and cyclin D1 genes by thyroid hormone in mammary epithelial cells. Mol Carcinog,2002; 34(1):25-34.
[28]Kuijpens JL, Nyklictek L, Louwman MW, et al. Hypothyroidism might be related to breast cancer in post-menopausal women. Thyroid,2005; 15(11): 1253-1259.
[29]Cristofanilli M, Yamamura Y, Kau SW, et al. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer,2005; 103(6):1122-1128.
[30]Martinez-Iglesias O, Garcia-Silva S, Regadera J, et al. Hypothyroidism enhances tumor invasiveness and metastasis development. PLoS One,2009; 29,4(7):6428.
[31]Sandhu MK, Brezden-Masley C, Lipscombe LL, et al. Autoimmune hypothyro-idism and breast cancer in the elderly. Breast Cancer Res Treat,2009; 115(3):635-641.
[32]Fierabracci P, Pinchera A, Campani D, et al. Association between breast cancer and autoimmune thyroid disorders:no increase of lymphocytic infiltrates in breast malignant tissues. J Endocrinol Invest,2006; 29(3):248-251.
[33]Drugarin D, Negru S, Koreck, et al. The pattern of a Thl cytokinein autoimmune thyroiditis.Immunol Lett,2000; 71(2):73-77.
[34]Turken O, Narln Y, Demlrbas S, et al. Breast cancer in association with Thyroid disorders. Breast Cancer Res,2003; 5(5):R110-R113.
[35]Gogas J, Kouskos E, Tseleni-Balafouta S, et al. Autoimmune thyroid disease in women with breast carcinoma. Eur J Surg Oncol,2001; 27(7):626-630.
[36]Giustarini E, Pinchera A, Fierabracci P, et al. Thyroid autoimmunity in patients with malignant and benign breast diseases before surgery. Eur J Endocrinol,2006; 154(5):645-649.
[37]Ditsch N, Liebhardt S, Von Koch F, et al. Thyroid function in breast cancer patients. Anticancer Res,2010; 30(5):1713-1717.
[38]Giani C, Fierabracci P, Bonacci R, et al. Relationship between breast cancer and thyroid disease:relevance of autoimmune thyoid disorders in breast malignancy. Clin Endocrinol Metab,1996; 81(3):990-994.
[39]Shering SG, Zbur AP, Moriaty M, et al. Thyroid disease and breast cancer. Eur J cancer,1996; 5(6):504-506.
[40]Cengiz O, Bozkurt B, Unal B, et al. The relationship between prognostic factors of breast cancer and thyroid disorders in Turkish women. J Surg Oncol,2004; 87(1):19-25.
[41]熊雅玲,徐贵颖,佟凌霞,等.彩色多普勒超声对乳腺肿瘤与甲状腺改变的关系观察.中国超声医学杂志,2000；16(8)：596-598.
[42]董威,夏稻子,刘颖.彩色多普勒超声对乳腺疾病与甲状腺关系的临床研究.中国超声诊断杂志,2003；4(6)：424-426.
[43]Sadetzki S, Calderon-Margalit R, Peretz C, et al. Second primary breast cancer and thyoid cancers (Israel). Cancer Causes Control,2003; 14(4):367-375.
[44]Tanaka H, Tsukuma H, Koyama H, et al. Second primary cancers following breast cancer in the Japanese female population. Jpn J Cancer Res,2001; 92(1):1-8.
[45]Sandeep TC, Strachan MW, Reynold RM, et al. Second primary cancers in thyroid cancer patients. A multinational record linkage study. J Clin Endocrinal Metab,2006; 91(5):1819-1825.
[46]Simon MS, Tang MT, Bernstein L, et al. Do thyroid disorders increase the risk of breast cancer? Cancer Epidemiol Biomarkers Pre,2002; 11(12):1574-1578.
[47]Nio Y, Iguchi C, Itakura M, et al. High incidence of synchronous or metachronous breast cancer in patients with malignant and benign thyroid tumor or tumor-like disorders. Anticancer Res,2009; 29(5):1607-1610.
[48]Park JS, Oh KK, Kim EK, et al. Sonographic detection of thyroid cancer in breast cancer patients.Yonsei Med J,2007; 48(1):63-68.
[49]Garner CN, Ganetzky R, Brainard J, et al. Increased prevalence of breast cancer among patients with thyroid and parathyroid disease. Surgery,2007; 142(6):806-813.
[50]Chen AY, Levy L. Goepfert H, et al. The development of breast carcinoma in women with thyroid carcinoma. Cancer,2001; 92(2):225-231.
[51]Li CI, Roosing MA, Voigt LF, et al. Multiple primary breast and thyroid cancer:role of age at diagnosis and cancer treatments. Cancer Causes Control,2000; 11(9):805-811.
[52]Canchola AJ, Horn Ross PL, Purdie DM. Risk of second primary maligancies in wemen with papillary thyroid cancer. Am J Epidemiol,2006; 163 (6):521-527.
[53]Verkooijen RB, Smit JW, Romi jn JA, et al. The incidence of second primary tumors in the thyroid cancer patients is increased, but not related to treatment of thyroid cancer. Eur J Endocrine,2006;155(6):801-806.
[54]Bogazzi F, Bartalena L, Brogiomi S, et al. Comparison of radoiodine with radoiodeme plus lithium in the treatment of Graves' hyperthyroidism. J Clin Endocrinol Metab,1999; 84(2):499-503.
[55]国家药典委员会.中华人民共和国药典(一部).北京：化学工业出版社,2000：168.
[56]翟忠灿.藻药散加味治疗甲亢36例疗效观察.云南中医中药杂志,2002；23(3)：13.
[57]张志荭,张传平.舒肝消瘿汤治疗甲状腺功能亢进32例.实用中医杂志,2001；17(2)：9.
[58]王力田,王丽英,闫秀芳,等.昆布平衡液治疗碘缺乏病1898例.深圳中西医结合杂志,1997；7(2)：41.
[59]杨秋丽,谷凯锋,洪伟,等.自拟愈瘿汤治疗甲状腺良性肿物90例.吉林中医药,2002；22(5)：32.
[60]蔡卫华.中医辩证治疗亚急性甲状腺炎临床观察.现代中西医结合杂志,1999；8(12)：1999.
[61]郑翠瑛,潘汝瑾,罗苏生.海藻玉壶汤加减治疗甲亢临床观察.浙江中医学院学报.1994；18(3)：23.
[62]朱重光.治疗甲状腺机能亢进症的临床机会.河南中医,1993；13(1)：11.
[63]张淑芝.甲亢丸治疗甲状腺机能亢进症152例.黑龙江中医药,1987；(1)：43.
[64]党泽.甲亢煎治疗甲状腺机能亢进症50例.陕西中医,1991； (11)：489.
[65]解发良.中药为主治疗甲亢109例疗效观察.湖南中医杂志,1990； (2)：7.
[66]覃兆伟.辨证治疗乳腺囊性增生症120例.中华实用中西医杂志.2000；13(4)：701.
[67]陈红梅,刘正霞.乳安汤治疗乳腺增生症100例.中国民间疗法.2003；11(4)：39-40.
[68]王明松,铁钢.海藻昆布汤治疗乳腺增生病24例.实用中医药杂志.2004；20(6)：292-293.
[69]黄建国.消癖丹膏治疗乳腺小叶增生320例.中华实用中西医杂志.2003；3(16)：199.
[70]王瑞芬.中药配合微波治疗乳腺增生病60例疗效观察.新中医,2009；41(6)48-49.
[71]马栓全,蔡国良,许鹏光.消结止痛膏外贴治疗乳腺增生病132例.陕西中医,2008;29 (3):271.
[72]Chung JK. Sodium iodide symporter:its role in nuclear medicine. J Nucl Med,2002; 43(9):1188-1200.
[73]Upadhyay G, Singh R, Agarwal G, et al. Functional expression of sodium iodide symporter (NIS) in human breast cancer tissue. Breast Cancer Res Treat,2003; 77(2):157-165.
[74]Tanosaki S, Ikezoe T, Heaney A, et al. Effect of ligands of nuclear hormone receptors on sodium/iodide symporter expression and activity in breast cells. Breast Cancer Res Treat,2003; 79(3):335-345.
[75]Kogai T, Schultz J, Johnson LS, et al. Retinoic acid induces sodium/ iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line. Proc Natl Acad Sci USA,2000; 97(15):8519-8524.
[76]Hall LC, Salazar EP, Kane SR, et al. Effect of thyroid hormones on human breast cancer cell proliferation. J Steroid Biochem Mol Biol,2008; 109(1-2):57-66.
[77]Nogueira CR, Brentani MM J. Triiodothyronine mimics the effects of estrogen in breast cancer cell lines. Steroid Biochem Molec Biol,1996; 59(3):271-279.
[78]Dinda S, Sanchez A, Moudgil V. Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. Oncogene,2002; 21(5):761-768.
[79]肖青,唐宗山,黄宗干,等.昆布多糖硫酸酯对急性髓性白血病HL-60细胞的调控.重庆医科大学学报,2003；28(3)：328-330.
[80]肖青,董蒲江,胡妮妮,等.昆布多糖硫酸酯抑制BxPC-3细胞增殖的实验研究.重庆医学,2004；33(3)：417-418.
[81]董蒲江,姚榛祥.LAMS抑制肝癌细胞增殖和促凝活性的实验研究.重庆医科大学学报,2001；26(4)：391-392.
[82]徐中平,张华坤,宋剑秋,等.酶解海带饮料的制作及其抗肿瘤和免疫调节作用的研究.食品科学,1999；18(9)：51.
[83]薜静波,刘希英,张鸿芬,等.海带多糖对小鼠腹腔巨噬细胞的激活作用.中国海洋药物,1999；18(3)：23.
[84]王庭欣,蒋东升,马晓彤,等.海带多糖对小鼠H22实体瘤的抑制作用.卫生毒理学杂志,2000；14(4)：242.
[85]YuLiu, QingDing, LiLiang, et al. Inhibition of growth and metastasis of human colorectal carcinoma cells by laminarin. Chinese Journal of Clinical Rehabilitation,2003; 7(26):3588-3589.
[86]Haroun-Bouhedja F, Lindenmeyer F, Lu H, et al. In vitro effects of fucans on MDA-MB231 tumor cell adhesion and invasion. Anticancer Res,2002; 22(4):2285-2292.
[87]李振波,丘和明.活血化瘀法治疗恶性肿瘤的讨论.中国中西医结合杂志,1996；16(9)：559-561.
[88]李树玲.乳腺肿瘤学.北京：科学技术文献出版社,2000,第1版：535-537.
[89]尚德俊.新编中医外科学.济南：济南出版社,1995,第1版：103.
[90]陆德铭.实用中医乳房病学.上海：上海中医学院出版社,1993,第1版：209.
[91]赵尚华.中医外科学.北京：人民卫生出版社,2008,第1版：138-144.
[92]李曰庆.中医外科学.北京：中国中医药出版社,2002,第1版：133-139.
[93]Guernsey DL. Thyroid hormone action. Cancer J,1993; 6(1):4-10.
[94]Goldman MB. Thyroid diseases and breast cancer. Epidemiol Rev,1990; 12:16-28.
[95]Zhou-Li F, Albaladejo V, Pharaboz MOJ, et al. Antiestrogens prevent the stimulatory effects of L-triiodothyronine on cell proliferation. Endocrinology,1992; 130(3):1145-1152.
[96]Hoffman DA, McCoaney WM, Brinton LA, et al. Breast cancer in hypothyroid women using thyroid supplements. JAMA,1984; 251(5):616-619.
[97]Smyth PPA. Thyroid disease and breast cancer. Endocrinol Invest,1993; 16(5):396-401.
[98]Martinez MB, Ruan M, Fitzpatrick A. Altered response to thyroid hormones by breast and ovarian cancer cells. Anticancer Res,2000; 20 (6B):4141-4146.
[99]Killbane MT, Ajjan RA, Weetman AP, et al. Tissue iodine content and serum-mediated I125 uptake-blocking activity in breast cancer. J Clin Endocrinol Metab,2000; 85(3):1245-1250.
[100]Yarden RI, Wilson MA, Chrysogelos SA. Estrogen suppression of in breast cancer cells:A possible mechanism to modulate growth. J Cell Biochem,2001; suppl36:232-246.
[101]Debski M, Debska L, Bar-Andziak E. Triiodothyronine receptors (TR) are present in breast cancer tissues. Endokrynol Pol,2006; 57(3):223-229.
[102]施华.乳腺癌激素受体检测及其临床意义.中国综合临床,2004；20(9)：860-861.
[103]Gonzalez-Sancho JM, Garcia V, Bonilla F, et al. Thyroid hormone receptors/ THR genes in human cancer. Cancer Lett,2003; 192(2):121-132.
[104]Conde I, Paniagua R, Zamora J, et al. Influence of thyroid hormone receptors on breast cancer cell proliferation. Ann Oncol,2006; 17(1):60-64.
[105]Martinez-Iglesias O, Garcia-Silva S, Tenbaum SP, et al. Thyroid hormone receptor betal acts as a potent suppressor of tumor invasiveness and metastasis. Cancer Res,2009; 69(2):501-509.
[106]Vorter RH. Benign and maligant breast disease and the thyroid function. Eur J Cancer Clin Oncol,1987; 2(2):255.
[107]Jung SY, Han W, Lee JW, et al. Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer. Ann Surg Oncol,2009; 16(5):1112-1121.
[108]Jalava P, Kuopio T, Juntti-Patinen L, et al. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardize-d mitotic index. Histopathology,2006; 48(6):674-682.
[109]Miglietta L, Vanella P, Canobbio L, Prognostic value of estrogen receptor and ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis. Oncology,2010; 79(3-4):255-61.
[110]Viale G, Regan MM, Mastropasqua MG, et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst,2008; 100(3):207-212.
[111]Lau R, Grimson R, Sansome C, et al. Low levels of cell cycle inhibitor p27kipl combined with high levels of Ki-67 predict shortened disease-free survival in T1 and T2 invasive breast carcinomas. Int J Oncol,2001; 18(1): 17-23.
[112]Railo M, Lundin J, Haglund C, et al. Ki-67, p53, ER receptors, ploidy and S phase as long-term prognostic factors in T1 nodenegative breast cancer. Tumour Biol,2007; 28(1):45-51.
[113]Miglietta L, Vanella P, Canobbio L, et al. Prognostic value of estrogen receptor and ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis. Oncology,2010; 79(3-4):255-261.
[114]Goldhirsch A, Ingle JN, Gelber RD,et al.Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol,2009; 20(8):1319-1329.
[115]罗振麟.肝脏与甲状腺.临床肝胆病杂志,1988；2(2)：7-9.
[116]钟永亮,唐容德.肝主疏泄与甲亢病机的关系初探.湖南中医学院学报,1994；14(3)：14-16.
[117]李志强,陈津岩,何赞厚,等.四君子汤对脾虚证大鼠血清性激素和甲状腺激素水平的影响.河南中医,2008；28(3)：36-37.
[118]Weiss SJ, Philp NJ, Crollman EF. Iodide transport in a continuous line of cultured cells from rat thyroid. Endocrinology,1984; 114:1090-1098.
[119]薛静波,刘希英,张鸿芬.海带多糖对小鼠腹腔巨噬细胞的激活作用.中国海洋药物,1999；18(3)：23.
[120]Gartner R, Rank P, Ander B. The role of iodine and delta-iodolacton in growth and apoptosis of malignant thyroid epithelial cells and breast cancer cells. HORMONES,2010; 9(1):60-66.
[121]贾悦,唐伟,刘超.钠/碘转运体在治疗甲状腺恶性肿瘤治疗中的作用.国外医学内分泌分册,2003；23(1)：37-39.
[122]Barton KN, Tyson D, Stricker H, et al. GENIS:gene expression of sodium iodide symporter for noninvasive imaging of gene therapy vectors and quantification of gene expression in vivo. Mol Ther,2003; 8(3):508-518.
[2]Parkin DM, Fernandez LM. Use of statistics to assess the global burden of breast cancer. Breast J,2006; 12 Suppll:S70-S80.
[3]Lee JH, Yim SH, Won YJ, et al. Population-based breast cancer statistics in Korea during 1993-2002:incidence, mortality and survival. J Korean Med Sci,2007; 22 Suppl:S11-S16.
[4]Cancer incidence in five continents. Volume Ⅷ. IARC Sci Publ,2002; 7(155):1-781.
[5]王庆生,林晓萍.中国乳腺癌流行病学研究.2000全国肿瘤学术大会论文集,2000：308.
[6]罗学林.乳腺癌与甲状腺激素.国外医学肿瘤学分册,1981；8(5)：213-214.
[7]唐荣德,黄小兵,郭爱群等.江门市新会区甲状腺功能检测结果的调查分析.热带医学杂志,2005；5(6)：846-851.
[8]刘超,武晓泓.钠/碘转运体.国外医学内分泌分册,2000；20(2)：59-62.
[9]Cho JY, Leveille R, Kao R, et al. Hormonal regulation of radioiodide uptake activity and Na+/I-symporter expression in mammary glands. J Clin Endocrinol Metab,2000; 85(8):2936-2943.
[10]Goldman MB. Thyroid diseases and breast cancer. Epidemiol Rev,1990; 12:16-28.
[11]Zhou-Li F, Albaladejo V, Pharaboz MOJ, et al. Antiestrogens prevent the stimulatory effects of L-triiodothyronine on cell proliferation. Endocrinology,1992; 130:1145-1152.
[12]Oh HJ, Chung JK, Kang JH, et al. The relationship between expression of the sodium/iodide symporter gene and the status of hormoal receptors in human breast cancer tissue,2005; 37(4):247-250.
[13]Tazebay UH, Wapnir H, Levy 0, et al. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med,2000; 6(8):871-878.
[14]Smyth PP. The thyroid, iodine and breast cancer. Breast Cancer Res,2003; 5(5):235-238.
[15]Teas J, Hurley TG, Hebert JR, et al. Dietary seaweed modifies estrogen and phytoestrogen metabolism in healthy postmenopausal women. J Nutr,2009; 139(5):939-944.
[16]Yang YJ, Nam SJ, Kong G, et al. A case-control study on seaweed consumption and the risk of breast cancer. Br J Nutr,2010; 103(9):1345-1353.
[17]Haroun-Bouhedja F, Lindenmeyer F, Lu H, et al. In vitro effects of fucans on MDA-MB231 tumor cell adhesion and invasion. Anticancer Res,2002; 22(4):2285-2292.
[18]Liu JM, Bignon J, Haroun-Bouhedja F, et al. Inhibitory effect of fucoidan on the adhesion of adenocarcinoma cells to fibronectin. Anticancer Res, 2005; 25(3B):2129-2133.
[19]Funahashi H, Imai T, Tanaka Y. Wakame seaweed suppresses the prolifer-ation of 7,12-dimethylbenz(a)-anthracene-induced mammary tumors in rats. Jpn J Cancer Res,1999; 90(9):922-927.
[20]Shrivastava A, Tiwan M, Sinha RA, et al. Molecular iodine induces caspase-independent apopotosis in human breast carcinoma cells involving the mitochondria-mediated pathway. J Biol Chem,2006; 281 (28):19762-19771.
[21]Tang HY, Lin HY, Zhang S, et al. Thyroid hormone causes mitogen activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor. Endocrinology,2004; 145(7):3265-3272.
[22]Cestari SH, Figueiredo NB, Conde SJ, et al. Influence of estradiol and triiodothyronine T3 on breast cancer cell lines proliferation and expression of estrogen and thyroid hormone receptors. Arq Bras Endocrinol Metabol,2009; 53(7):859-864.
[23]Gonzalez-Sancho JM, Alvarez-Dolado M, Caelles C, et al. Inhibition of tenascin-C expression in mammary epithelial cells by thyroid hormone. Mol Carcinog,1999; 24(2):99-107.
[24]Gago-Dominguez M, Castelao JE. Role of lipid peroxidation, and oxidative stress in the association between thyroid diseases and breast cancer. Crit Rev Oncol Hematol,2008; 68(2):107-114.
[25]Tosovic A, Bondeson AG, Bondeson L, et al. Prospectively measured triiodothyronine levels are positively associated with breast cancer risk in postmenopausal women. Breast Cancer Res,2010; 12(3):R33.
[26]Saraiva PP, Figueiredo NB, Padovani CR.et al. Profile of thyroid hormones in breast cancer patients. Braz J Med Biol Res,2005; 38 (5):761-765.
[27]Gonzalez-Sancho JM, Figueroa A, Lopez-Barahona M, et al. Inhibition of proliferation and expression of T1 and cyclin D1 genes by thyroid hormone in mammary epithelial cells. Mol Carcinog,2002; 34(1):25-34.
[28]Kuijpens JL, Nyklictek L, Louwman MW, et al. Hypothyroidism might be related to breast cancer in post-menopausal women. Thyroid,2005; 15(11): 1253-1259.
[29]Cristofanilli M, Yamamura Y, Kau SW, et al. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer,2005; 103(6):1122-1128.
[30]Martinez-Iglesias O, Garcia-Silva S, Regadera J, et al. Hypothyroidism enhances tumor invasiveness and metastasis development. PLoS One,2009; 29,4(7):6428.
[31]Sandhu MK, Brezden-Masley C, Lipscombe LL, et al. Autoimmune hypothyro-idism and breast cancer in the elderly. Breast Cancer Res Treat,2009; 115(3):635-641.
[32]Fierabracci P, Pinchera A, Campani D, et al. Association between breast cancer and autoimmune thyroid disorders:no increase of lymphocytic infiltrates in breast malignant tissues. J Endocrinol Invest,2006; 29(3):248-251.
[33]Drugarin D, Negru S, Koreck, et al. The pattern of a Thl cytokinein autoimmune thyroiditis.Immunol Lett,2000; 71(2):73-77.
[34]Turken O, Narln Y, Demlrbas S, et al. Breast cancer in association with Thyroid disorders. Breast Cancer Res,2003; 5(5):R110-R113.
[35]Gogas J, Kouskos E, Tseleni-Balafouta S, et al. Autoimmune thyroid disease in women with breast carcinoma. Eur J Surg Oncol,2001; 27(7):626-630.
[36]Giustarini E, Pinchera A, Fierabracci P, et al. Thyroid autoimmunity in patients with malignant and benign breast diseases before surgery. Eur J Endocrinol,2006; 154(5):645-649.
[37]Ditsch N, Liebhardt S, Von Koch F, et al. Thyroid function in breast cancer patients. Anticancer Res,2010; 30(5):1713-1717.
[38]Giani C, Fierabracci P, Bonacci R, et al. Relationship between breast cancer and thyroid disease:relevance of autoimmune thyoid disorders in breast malignancy. Clin Endocrinol Metab,1996; 81(3):990-994.
[39]Shering SG, Zbur AP, Moriaty M, et al. Thyroid disease and breast cancer. Eur J cancer,1996; 5(6):504-506.
[40]Cengiz O, Bozkurt B, Unal B, et al. The relationship between prognostic factors of breast cancer and thyroid disorders in Turkish women. J Surg Oncol,2004; 87(1):19-25.
[41]熊雅玲,徐贵颖,佟凌霞,等.彩色多普勒超声对乳腺肿瘤与甲状腺改变的关系观察.中国超声医学杂志,2000；16(8)：596-598.
[42]董威,夏稻子,刘颖.彩色多普勒超声对乳腺疾病与甲状腺关系的临床研究.中国超声诊断杂志,2003；4(6)：424-426.
[43]Sadetzki S, Calderon-Margalit R, Peretz C, et al. Second primary breast cancer and thyoid cancers (Israel). Cancer Causes Control,2003; 14(4):367-375.
[44]Tanaka H, Tsukuma H, Koyama H, et al. Second primary cancers following breast cancer in the Japanese female population. Jpn J Cancer Res,2001; 92(1):1-8.
[45]Sandeep TC, Strachan MW, Reynold RM, et al. Second primary cancers in thyroid cancer patients. A multinational record linkage study. J Clin Endocrinal Metab,2006; 91(5):1819-1825.
[46]Simon MS, Tang MT, Bernstein L, et al. Do thyroid disorders increase the risk of breast cancer? Cancer Epidemiol Biomarkers Pre,2002; 11(12):1574-1578.
[47]Nio Y, Iguchi C, Itakura M, et al. High incidence of synchronous or metachronous breast cancer in patients with malignant and benign thyroid tumor or tumor-like disorders. Anticancer Res,2009; 29(5):1607-1610.
[48]Park JS, Oh KK, Kim EK, et al. Sonographic detection of thyroid cancer in breast cancer patients.Yonsei Med J,2007; 48(1):63-68.
[49]Garner CN, Ganetzky R, Brainard J, et al. Increased prevalence of breast cancer among patients with thyroid and parathyroid disease. Surgery,2007; 142(6):806-813.
[50]Chen AY, Levy L. Goepfert H, et al. The development of breast carcinoma in women with thyroid carcinoma. Cancer,2001; 92(2):225-231.
[51]Li CI, Roosing MA, Voigt LF, et al. Multiple primary breast and thyroid cancer:role of age at diagnosis and cancer treatments. Cancer Causes Control,2000; 11(9):805-811.
[52]Canchola AJ, Horn Ross PL, Purdie DM. Risk of second primary maligancies in wemen with papillary thyroid cancer. Am J Epidemiol,2006; 163 (6):521-527.
[53]Verkooijen RB, Smit JW, Romi jn JA, et al. The incidence of second primary tumors in the thyroid cancer patients is increased, but not related to treatment of thyroid cancer. Eur J Endocrine,2006;155(6):801-806.
[54]Bogazzi F, Bartalena L, Brogiomi S, et al. Comparison of radoiodine with radoiodeme plus lithium in the treatment of Graves' hyperthyroidism. J Clin Endocrinol Metab,1999; 84(2):499-503.
[55]国家药典委员会.中华人民共和国药典(一部).北京：化学工业出版社,2000：168.
[56]翟忠灿.藻药散加味治疗甲亢36例疗效观察.云南中医中药杂志,2002；23(3)：13.
[57]张志荭,张传平.舒肝消瘿汤治疗甲状腺功能亢进32例.实用中医杂志,2001；17(2)：9.
[58]王力田,王丽英,闫秀芳,等.昆布平衡液治疗碘缺乏病1898例.深圳中西医结合杂志,1997；7(2)：41.
[59]杨秋丽,谷凯锋,洪伟,等.自拟愈瘿汤治疗甲状腺良性肿物90例.吉林中医药,2002；22(5)：32.
[60]蔡卫华.中医辩证治疗亚急性甲状腺炎临床观察.现代中西医结合杂志,1999；8(12)：1999.
[61]郑翠瑛,潘汝瑾,罗苏生.海藻玉壶汤加减治疗甲亢临床观察.浙江中医学院学报.1994；18(3)：23.
[62]朱重光.治疗甲状腺机能亢进症的临床机会.河南中医,1993；13(1)：11.
[63]张淑芝.甲亢丸治疗甲状腺机能亢进症152例.黑龙江中医药,1987；(1)：43.
[64]党泽.甲亢煎治疗甲状腺机能亢进症50例.陕西中医,1991； (11)：489.
[65]解发良.中药为主治疗甲亢109例疗效观察.湖南中医杂志,1990； (2)：7.
[66]覃兆伟.辨证治疗乳腺囊性增生症120例.中华实用中西医杂志.2000；13(4)：701.
[67]陈红梅,刘正霞.乳安汤治疗乳腺增生症100例.中国民间疗法.2003；11(4)：39-40.
[68]王明松,铁钢.海藻昆布汤治疗乳腺增生病24例.实用中医药杂志.2004；20(6)：292-293.
[69]黄建国.消癖丹膏治疗乳腺小叶增生320例.中华实用中西医杂志.2003；3(16)：199.
[70]王瑞芬.中药配合微波治疗乳腺增生病60例疗效观察.新中医,2009；41(6)48-49.
[71]马栓全,蔡国良,许鹏光.消结止痛膏外贴治疗乳腺增生病132例.陕西中医,2008;29 (3):271.
[72]Chung JK. Sodium iodide symporter:its role in nuclear medicine. J Nucl Med,2002; 43(9):1188-1200.
[73]Upadhyay G, Singh R, Agarwal G, et al. Functional expression of sodium iodide symporter (NIS) in human breast cancer tissue. Breast Cancer Res Treat,2003; 77(2):157-165.
[74]Tanosaki S, Ikezoe T, Heaney A, et al. Effect of ligands of nuclear hormone receptors on sodium/iodide symporter expression and activity in breast cells. Breast Cancer Res Treat,2003; 79(3):335-345.
[75]Kogai T, Schultz J, Johnson LS, et al. Retinoic acid induces sodium/ iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line. Proc Natl Acad Sci USA,2000; 97(15):8519-8524.
[76]Hall LC, Salazar EP, Kane SR, et al. Effect of thyroid hormones on human breast cancer cell proliferation. J Steroid Biochem Mol Biol,2008; 109(1-2):57-66.
[77]Nogueira CR, Brentani MM J. Triiodothyronine mimics the effects of estrogen in breast cancer cell lines. Steroid Biochem Molec Biol,1996; 59(3):271-279.
[78]Dinda S, Sanchez A, Moudgil V. Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. Oncogene,2002; 21(5):761-768.
[79]肖青,唐宗山,黄宗干,等.昆布多糖硫酸酯对急性髓性白血病HL-60细胞的调控.重庆医科大学学报,2003；28(3)：328-330.
[80]肖青,董蒲江,胡妮妮,等.昆布多糖硫酸酯抑制BxPC-3细胞增殖的实验研究.重庆医学,2004；33(3)：417-418.
[81]董蒲江,姚榛祥.LAMS抑制肝癌细胞增殖和促凝活性的实验研究.重庆医科大学学报,2001；26(4)：391-392.
[82]徐中平,张华坤,宋剑秋,等.酶解海带饮料的制作及其抗肿瘤和免疫调节作用的研究.食品科学,1999；18(9)：51.
[83]薜静波,刘希英,张鸿芬,等.海带多糖对小鼠腹腔巨噬细胞的激活作用.中国海洋药物,1999；18(3)：23.
[84]王庭欣,蒋东升,马晓彤,等.海带多糖对小鼠H22实体瘤的抑制作用.卫生毒理学杂志,2000；14(4)：242.
[85]YuLiu, QingDing, LiLiang, et al. Inhibition of growth and metastasis of human colorectal carcinoma cells by laminarin. Chinese Journal of Clinical Rehabilitation,2003; 7(26):3588-3589.
[86]Haroun-Bouhedja F, Lindenmeyer F, Lu H, et al. In vitro effects of fucans on MDA-MB231 tumor cell adhesion and invasion. Anticancer Res,2002; 22(4):2285-2292.
[87]李振波,丘和明.活血化瘀法治疗恶性肿瘤的讨论.中国中西医结合杂志,1996；16(9)：559-561.
[88]李树玲.乳腺肿瘤学.北京：科学技术文献出版社,2000,第1版：535-537.
[89]尚德俊.新编中医外科学.济南：济南出版社,1995,第1版：103.
[90]陆德铭.实用中医乳房病学.上海：上海中医学院出版社,1993,第1版：209.
[91]赵尚华.中医外科学.北京：人民卫生出版社,2008,第1版：138-144.
[92]李曰庆.中医外科学.北京：中国中医药出版社,2002,第1版：133-139.
[93]Guernsey DL. Thyroid hormone action. Cancer J,1993; 6(1):4-10.
[94]Goldman MB. Thyroid diseases and breast cancer. Epidemiol Rev,1990; 12:16-28.
[95]Zhou-Li F, Albaladejo V, Pharaboz MOJ, et al. Antiestrogens prevent the stimulatory effects of L-triiodothyronine on cell proliferation. Endocrinology,1992; 130(3):1145-1152.
[96]Hoffman DA, McCoaney WM, Brinton LA, et al. Breast cancer in hypothyroid women using thyroid supplements. JAMA,1984; 251(5):616-619.
[97]Smyth PPA. Thyroid disease and breast cancer. Endocrinol Invest,1993; 16(5):396-401.
[98]Martinez MB, Ruan M, Fitzpatrick A. Altered response to thyroid hormones by breast and ovarian cancer cells. Anticancer Res,2000; 20 (6B):4141-4146.
[99]Killbane MT, Ajjan RA, Weetman AP, et al. Tissue iodine content and serum-mediated I125 uptake-blocking activity in breast cancer. J Clin Endocrinol Metab,2000; 85(3):1245-1250.
[100]Yarden RI, Wilson MA, Chrysogelos SA. Estrogen suppression of in breast cancer cells:A possible mechanism to modulate growth. J Cell Biochem,2001; suppl36:232-246.
[101]Debski M, Debska L, Bar-Andziak E. Triiodothyronine receptors (TR) are present in breast cancer tissues. Endokrynol Pol,2006; 57(3):223-229.
[102]施华.乳腺癌激素受体检测及其临床意义.中国综合临床,2004；20(9)：860-861.
[103]Gonzalez-Sancho JM, Garcia V, Bonilla F, et al. Thyroid hormone receptors/ THR genes in human cancer. Cancer Lett,2003; 192(2):121-132.
[104]Conde I, Paniagua R, Zamora J, et al. Influence of thyroid hormone receptors on breast cancer cell proliferation. Ann Oncol,2006; 17(1):60-64.
[105]Martinez-Iglesias O, Garcia-Silva S, Tenbaum SP, et al. Thyroid hormone receptor betal acts as a potent suppressor of tumor invasiveness and metastasis. Cancer Res,2009; 69(2):501-509.
[106]Vorter RH. Benign and maligant breast disease and the thyroid function. Eur J Cancer Clin Oncol,1987; 2(2):255.
[107]Jung SY, Han W, Lee JW, et al. Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer. Ann Surg Oncol,2009; 16(5):1112-1121.
[108]Jalava P, Kuopio T, Juntti-Patinen L, et al. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardize-d mitotic index. Histopathology,2006; 48(6):674-682.
[109]Miglietta L, Vanella P, Canobbio L, Prognostic value of estrogen receptor and ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis. Oncology,2010; 79(3-4):255-61.
[110]Viale G, Regan MM, Mastropasqua MG, et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst,2008; 100(3):207-212.
[111]Lau R, Grimson R, Sansome C, et al. Low levels of cell cycle inhibitor p27kipl combined with high levels of Ki-67 predict shortened disease-free survival in T1 and T2 invasive breast carcinomas. Int J Oncol,2001; 18(1): 17-23.
[112]Railo M, Lundin J, Haglund C, et al. Ki-67, p53, ER receptors, ploidy and S phase as long-term prognostic factors in T1 nodenegative breast cancer. Tumour Biol,2007; 28(1):45-51.
[113]Miglietta L, Vanella P, Canobbio L, et al. Prognostic value of estrogen receptor and ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis. Oncology,2010; 79(3-4):255-261.
[114]Goldhirsch A, Ingle JN, Gelber RD,et al.Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol,2009; 20(8):1319-1329.
[115]罗振麟.肝脏与甲状腺.临床肝胆病杂志,1988；2(2)：7-9.
[116]钟永亮,唐容德.肝主疏泄与甲亢病机的关系初探.湖南中医学院学报,1994；14(3)：14-16.
[117]李志强,陈津岩,何赞厚,等.四君子汤对脾虚证大鼠血清性激素和甲状腺激素水平的影响.河南中医,2008；28(3)：36-37.
[118]Weiss SJ, Philp NJ, Crollman EF. Iodide transport in a continuous line of cultured cells from rat thyroid. Endocrinology,1984; 114:1090-1098.
[119]薛静波,刘希英,张鸿芬.海带多糖对小鼠腹腔巨噬细胞的激活作用.中国海洋药物,1999；18(3)：23.
[120]Gartner R, Rank P, Ander B. The role of iodine and delta-iodolacton in growth and apoptosis of malignant thyroid epithelial cells and breast cancer cells. HORMONES,2010; 9(1):60-66.
[121]贾悦,唐伟,刘超.钠/碘转运体在治疗甲状腺恶性肿瘤治疗中的作用.国外医学内分泌分册,2003；23(1)：37-39.
[122]Barton KN, Tyson D, Stricker H, et al. GENIS:gene expression of sodium iodide symporter for noninvasive imaging of gene therapy vectors and quantification of gene expression in vivo. Mol Ther,2003; 8(3):508-518.